Intech Investment Management LLC lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 276.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,749 shares of the medical instruments supplier’s stock after acquiring an additional 34,333 shares during the quarter. Intech Investment Management LLC’s holdings in West Pharmaceutical Services were worth $17,333,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Silver Oak Securities Incorporated boosted its holdings in West Pharmaceutical Services by 22.4% in the third quarter. Silver Oak Securities Incorporated now owns 1,950 shares of the medical instruments supplier’s stock valued at $780,000 after purchasing an additional 357 shares during the period. Bessemer Group Inc. grew its stake in West Pharmaceutical Services by 21.9% during the 3rd quarter. Bessemer Group Inc. now owns 1,189 shares of the medical instruments supplier’s stock worth $442,000 after purchasing an additional 214 shares in the last quarter. Harbour Investments Inc. grew its stake in West Pharmaceutical Services by 994.2% during the 3rd quarter. Harbour Investments Inc. now owns 755 shares of the medical instruments supplier’s stock worth $280,000 after purchasing an additional 686 shares in the last quarter. Virtus Advisers LLC purchased a new stake in West Pharmaceutical Services during the 3rd quarter worth about $37,000. Finally, Phoenix Financial Ltd. increased its holdings in West Pharmaceutical Services by 23.1% during the 3rd quarter. Phoenix Financial Ltd. now owns 815 shares of the medical instruments supplier’s stock worth $302,000 after purchasing an additional 153 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on WST shares. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. Barclays boosted their price objective on West Pharmaceutical Services from $440.00 to $500.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. UBS Group boosted their price objective on West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Citigroup upped their target price on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, TD Cowen raised their target price on shares of West Pharmaceutical Services from $420.00 to $500.00 and gave the company a “buy” rating in a report on Friday, October 30th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $424.67.
View Our Latest Stock Report on WST
Insider Activity
In other news, VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the completion of the transaction, the vice president directly owned 16,845 shares of the company’s stock, valued at approximately $5,740,944.45. This represents a 32.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 15,659 shares of company stock worth $5,443,749. Corporate insiders own 0.60% of the company’s stock.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services stock opened at $416.34 on Monday. The stock has a market cap of $29.00 billion, a P/E ratio of 46.73, a price-to-earnings-growth ratio of 2.53 and a beta of 1.13. The company has a fifty day simple moving average of $380.32 and a 200-day simple moving average of $320.84. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $438.27. The company has a current ratio of 2.82, a quick ratio of 2.10 and a debt-to-equity ratio of 0.07.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.20 by $0.46. The firm had revenue of $874.50 million for the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. West Pharmaceutical Services’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.96 earnings per share. Equities analysts expect that West Pharmaceutical Services, Inc. will post 9.45 EPS for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be issued a dividend of $0.26 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.67%.
West Pharmaceutical Services Profile
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Further Reading
- Five stocks we like better than West Pharmaceutical Services
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
